Capital Advisors Inc. OK grew its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 390,570 shares of the company’s stock after acquiring an additional 8,922 shares during the quarter. AbbVie comprises approximately 1.4% of Capital Advisors Inc. OK’s investment portfolio, making the stock its 15th biggest position. Capital Advisors Inc. OK’s holdings in AbbVie were worth $89,241,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Hengehold Capital Management LLC boosted its position in shares of AbbVie by 1.7% during the 4th quarter. Hengehold Capital Management LLC now owns 27,861 shares of the company’s stock valued at $6,366,000 after acquiring an additional 470 shares during the last quarter. Victory Financial Group LLC increased its position in AbbVie by 38.5% during the fourth quarter. Victory Financial Group LLC now owns 7,706 shares of the company’s stock worth $1,761,000 after purchasing an additional 2,141 shares during the last quarter. Bourgeon Capital Management LLC purchased a new position in AbbVie during the fourth quarter worth about $801,000. Lodestone Wealth Management LLC purchased a new position in AbbVie during the fourth quarter worth about $73,000. Finally, Frank Rimerman Advisors LLC boosted its holdings in AbbVie by 0.4% in the 4th quarter. Frank Rimerman Advisors LLC now owns 33,170 shares of the company’s stock valued at $7,579,000 after purchasing an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
Insider Buying and Selling at AbbVie
In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by insiders.
Key AbbVie News
- Positive Sentiment: Earnings momentum and guidance: AbbVie posted a quarterly EPS beat and raised FY?2026 guidance earlier this year, which supports investor confidence in near?term earnings and cash flow (background company report).
- Positive Sentiment: Analyst support: BMO (via TipRanks coverage) maintained a Buy rating and $258 price target, reinforcing bullish sentiment among institutional investors. AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
- Positive Sentiment: Institutional buying: Beacon Investment Advisory increased its stake in ABBV, signaling continued institutional interest. Beacon Investment Advisory Services Inc. Has $19.86 Million Stock Position in AbbVie Inc. $ABBV
- Positive Sentiment: Aesthetics business activity: Allergan Aesthetics (an AbbVie unit) launched promotional CoolMonth offers and presented safety/efficacy data at AAD — both support the aesthetics revenue story. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 AAD
- Positive Sentiment: Macro tax tailwind: Analysis shows corporate cash taxes fell materially under the new tax law, a factor that can boost free cash flow for large pharma including AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
- Neutral Sentiment: Stock commentary: MarketWatch notes ABBV rose but still slightly underperformed the broader market on the day; useful context for relative performance. AbbVie Inc. stock rises Tuesday, still underperforms market
- Neutral Sentiment: Upcoming event: AbbVie set its Q1 2026 earnings release and conference call for April 29 — an event that could drive volatility and provide fresh guidance. AbbVie to Host First-Quarter 2026 Earnings Conference Call
- Neutral Sentiment: Competitive messaging: AbbVie publicly defends Skyrizi’s efficacy edge as J&J launches Icotyde — shows competitive dynamics in immunology/dermatology but not an immediate structural change. As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge
- Negative Sentiment: Oncology pressure: Analyst coverage (Zacks) highlights 2026 headwinds for AbbVie’s oncology revenue — Imbruvica pricing pressure may weigh on top?line growth despite newer drug contributions. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
- Negative Sentiment: Lawsuit tied to Cerevel deal: A Bloomberg Law item says investors’ suit over the Cerevel deal involving Pfizer/Bain must proceed, which could raise legal risk/uncertainty around the transaction and reputational exposure. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
- Negative Sentiment: Peer M&A strengthens competition: Merck’s large oncology deal (Terns) reinforces competitive pressure in oncology — a potential headwind for AbbVie’s oncology growth narrative. Merck Just Made a Big Bet on a New Cancer Growth Engine
Analysts Set New Price Targets
Several research firms have recently weighed in on ABBV. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target for the company. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday, January 20th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their target price for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.
Check Out Our Latest Analysis on ABBV
AbbVie Stock Performance
Shares of ABBV stock opened at $217.39 on Wednesday. The firm’s 50 day moving average price is $222.00 and its 200-day moving average price is $224.65. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The firm has a market cap of $384.38 billion, a P/E ratio of 92.11, a P/E/G ratio of 0.74 and a beta of 0.34.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.
AbbVie Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s payout ratio is presently 293.22%.
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Further Reading
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
